Adinegara Lutfi Abas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adinegara Lutfi Abas has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Mila Nu Nu Htay
Centre for Population Health (CePH), Department of Social and Preventive Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
3 shared publications Nalini Sathiakumar
School of Public Health, University of Alabama at Birmingham. 1665 University Blvd, Birmingham, AL. 35294-0022
3 shared publicationsSoe Moe
3 shared publications- Thanigasalam Thevi
Hospital Melaka
3 shared publications Abdul Razzak Bin Mohd Said
2 shared publicationsMohammed Azman Bin Aziz Mohammed
2 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Knowledge E DMCC in Journal of Ophthalmic and Vision Research
- Vol. 21, 1-17
Comparison of Outcomes of Anterior Chamber Intraocular Lenses with Scleral-fixated Intraocular Lenses: A Systematic Review
The absence of adequate posterior capsule support—whether due to complicated cataract surgery, lens subluxation due to trauma or syndromes, or aphakia due to any other cause—necessitates a suitable intraocular lens (IOL), either an anterior chamber intraocular lens (ACIOL) or a scleral-fixated IOL. The absence of any systematic review in the English literature comparing ACIOL with scleral-fixated IOL prompted this study. We looked for clinical trials (randomized and controlled) comparing the outcomes of ACIOL with scleral-fixated IOLs through various search engines. The searched terms included anterior chamber intraocular lens, scleral-fixated intraocular lens, complicated cataract surgery, and secondary intraocular lens. All patients who had either an ACIOL or scleralfixated IOL were included. Risk of bias was assessed using the Cochrane Collaboration tools to ascertain the standard and quality of the trials. The outcomes studied were best-corrected visual acuity (BCVA) and intraoperative and postoperative complications. Seven trials were finally selected for analysis. There was no difference in BCVA between ACIOL and scleral-fixated IOL. There was also no difference in terms of complications, including retinal detachment, cystoid macular edema, glaucoma, uveitis, and vitreous prolapse, between the two groups. However, there was a higher chance of vitreous hemorrhage in the scleral-fixated group compared to ACIOL. Both ACIOL and scleralfixated IOLs appear to be used as safe options in current practice. Further multicenter randomized controlled trials are needed to clarify the benefits of each intervention and strengthen the validity of this review
- 2 November 2026
- Published by Knowledge E DMCC in Journal of Ophthalmic and Vision Research
- Vol. 21, 1-17
Open AccessComparison of Outcomes of Anterior Chamber Intraocular Lenses with Scleral-fixated Intraocular Lenses: A Systematic Review
The absence of adequate posterior capsule support—whether due to complicated cataract surgery, lens subluxation due to trauma or syndromes, or aphakia due to any other cause—necessitates a suitable intraocular lens (IOL), either an anterior chamber intraocular lens (ACIOL) or a scleral-fixated IOL. The absence of any systematic review in the English literature comparing ACIOL with scleral-fixated IOL prompted this study. We looked for clinical trials (randomized and controlled) comparing the outcomes of ACIOL with scleral-fixated IOLs through various search engines. The searched terms included anterior chamber intraocular lens, scleral-fixated intraocular lens, complicated cataract surgery, and secondary intraocular lens. All patients who had either an ACIOL or scleralfixated IOL were included. Risk of bias was assessed using the Cochrane Collaboration tools to ascertain the standard and quality of the trials. The outcomes studied were best-corrected visual acuity (BCVA) and intraoperative and postoperative complications. Seven trials were finally selected for analysis. There was no difference in BCVA between ACIOL and scleral-fixated IOL. There was also no difference in terms of complications, including retinal detachment, cystoid macular edema, glaucoma, uveitis, and vitreous prolapse, between the two groups. However, there was a higher chance of vitreous hemorrhage in the scleral-fixated group compared to ACIOL. Both ACIOL and scleralfixated IOLs appear to be used as safe options in current practice. Further multicenter randomized controlled trials are needed to clarify the benefits of each intervention and strengthen the validity of this review
- Open Access
- 1 March 2026
- Published by Korean Society of Medical Education in Korean Journal of Medical Education
- Vol. 38 (1) , 116-119
Navigating ethical considerations and challenges in medical education research
Korean Journal of Medical Education
- 1 March 2026
- Published by Korean Society of Medical Education in Korean Journal of Medical Education
- Vol. 38 (1) , 116-119
Open AccessNavigating ethical considerations and challenges in medical education research
Korean Journal of Medical Education
- Open Access
- 15 March 2024
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 27
Knowledge and awareness of neglected tropical diseases and control strategies among healthcare students in five Asian countries: A cross-sectional study
- 15 March 2024
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 27
Open AccessKnowledge and awareness of neglected tropical diseases and control strategies among healthcare students in five Asian countries: A cross-sectional study
- Open Access
- 27 September 2021
- Published by Springer Nature in BMC Ophthalmology
- Vol. 21 (1) , 1-11
Comparison between the English and Bahasa Malaysia language versions of the Visual Functioning Questionnaire (VFQ-25) for use in patients with cataracts
Background: We conducted the study to compare the psychometric properties of the English version of the Questionnaire and the Bahasa Malaysia (Malay Language) version regarding the vision-related Quality of Life of patients with cataracts. Methods: The Malay version was translated by two independent translators who were well versed in both languages. We carried out a cross-sectional study collecting data between June 2017 and March 2018 in the pre-operative Eye Clinic of Hospital Melaka with 224 respondents (mean age 66.8 years) and another 204 respondents (mean age 64.3 years) participating in the English version and Malay version of the Questionnaire respectively. Methods used to validate the standard questionnaire included the use of construct validity via factor analysis and the deployment of reliability test through assessment of internal consistency via Cronbach’s alpha. Results: We observed both English and Bahasa Malaysia versions to have high reliability with Cronbach’s alpha values of 0.90 and above in factors on difficulty with activities and responses to vision problems. Exploratory factor analysis performed revealed that the three-factor model fits the data well for the English version of the questionnaire - difficulty with activities (23.81 % of variance), responses to vision problem (22.22 % of variance) and general health and vision (14.68 % of variance). The Bahasa Malaysia version of the questionnaire produced three factors with two of the factors resembling the factors from the original version of the questionnaire - difficulty with activities (24.3 % of variance) and responses to vision problem (23.7 % of variance). Item response theory analysis revealed that these factors for both English and Bahasa Malaysia versions comprised of adequately fitted items. Conclusion: The present study observed that both the English and Bahasa Malaysia versions of the NEI VFQ-25 have comparable construct validity to the original American version. With high validity and reliability, the tool shall be able to provide health care providers the assessment of impact due to cataract and other ophthalmic conditions on the vision-related quality of life of ophthalmic patients.
- 27 September 2021
- Published by Springer Nature in BMC Ophthalmology
- Vol. 21 (1) , 1-11
Open AccessComparison between the English and Bahasa Malaysia language versions of the Visual Functioning Questionnaire (VFQ-25) for use in patients with cataracts
Background: We conducted the study to compare the psychometric properties of the English version of the Questionnaire and the Bahasa Malaysia (Malay Language) version regarding the vision-related Quality of Life of patients with cataracts. Methods: The Malay version was translated by two independent translators who were well versed in both languages. We carried out a cross-sectional study collecting data between June 2017 and March 2018 in the pre-operative Eye Clinic of Hospital Melaka with 224 respondents (mean age 66.8 years) and another 204 respondents (mean age 64.3 years) participating in the English version and Malay version of the Questionnaire respectively. Methods used to validate the standard questionnaire included the use of construct validity via factor analysis and the deployment of reliability test through assessment of internal consistency via Cronbach’s alpha. Results: We observed both English and Bahasa Malaysia versions to have high reliability with Cronbach’s alpha values of 0.90 and above in factors on difficulty with activities and responses to vision problems. Exploratory factor analysis performed revealed that the three-factor model fits the data well for the English version of the questionnaire - difficulty with activities (23.81 % of variance), responses to vision problem (22.22 % of variance) and general health and vision (14.68 % of variance). The Bahasa Malaysia version of the questionnaire produced three factors with two of the factors resembling the factors from the original version of the questionnaire - difficulty with activities (24.3 % of variance) and responses to vision problem (23.7 % of variance). Item response theory analysis revealed that these factors for both English and Bahasa Malaysia versions comprised of adequately fitted items. Conclusion: The present study observed that both the English and Bahasa Malaysia versions of the NEI VFQ-25 have comparable construct validity to the original American version. With high validity and reliability, the tool shall be able to provide health care providers the assessment of impact due to cataract and other ophthalmic conditions on the vision-related quality of life of ophthalmic patients.
- Open Access
- 1 July 2021
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 11, 100759
How healthcare workers are coping with mental health challenges during COVID-19 pandemic? - A cross-sectional multi-countries study
- 1 July 2021
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 11, 100759
Open AccessHow healthcare workers are coping with mental health challenges during COVID-19 pandemic? - A cross-sectional multi-countries study
- Open Access
- 30 June 2021
- Published by Manipal College of Nursing, Manipal Academy of Higher Education in Manipal Journal of Medical Sciences
- Vol. 6 (1) , 6
Comparative study of Perinatal Mortality, Stillbirths, and Neonatal Mortality from 2010 to 2018 in developing and developed nations with reference to Malaysia
Background: Malaysia being an emerging economy has done well in the health sector. The perinatal mortality is reduced significantly but a slight upward trend was seen after 2015 in less developed states. This prompted us to conduct a review of perinatal, stillbirth, and neonatal deaths in Malaysia and compare them with other developing and developed countries. Aims and objectives: To find out: (1) Perinatal, neonatal and stillbirth rates from 2010 to 2018 in Malaysia, and (2) Compare it with developed and developing countries for the same duration. (3) To study contributary factors responsible for perinatal mortality, stillbirths and neonatal deaths and recommend the action plan to reduce it. Materials and Methods: Data related to perinatal, stillbirths and early neonatal mortality was searched from September 2020 to October 2020 using PubMed, Google, Google Scholar, Embase, EBSCO, Elsevier, and NIH/National Library of Medicine. Statistical Analysis: Analysis was done using Excel and StatCalc. Results: Mean perinatal mortality, stillbirth, and early neonatal mortality rates in Malaysia are 7.8, 4.72, 3 per 1000 respectively, which are almost half as that of Brazil which has PMR 17/1000, SBR 9.11/1000, ENMR 7.15/1000 live births. However, these values are twice as high as Singapore and Netherlands. Singapore has the lowest mortality rates; PMR 3.2, SBR 2.33 and ENMR 1.21 per 1000. Comparatively, India had the highest PMR of 26/1000 and ENMR of 22/1000 live births. Regional variations are seen in Malaysia, Brazil, India, and Netherlands. Main causes of perinatal mortality include pre-term births, hypertensive disorders of pregnancy, asphyxia, prematurity and low birth weight, congenital malformations in developing and emerging countries. Whereas, in developed nations, congenital malformation, aneuploidy, asphyxia and antepartum haemorrhage (APH) constitute the main causes. Major risk factors were maternal age, primigravida, obesity and diabetes. Conclusion: PMR, ENMR, SBR are high in low-income states in Malaysia, India, and Brazil. Contributory factors can be low income, poor education, lack of health-seeking behaviour. Mortalities can be reduced by educating women regarding pregnancy, nutrition, spacing of pregnancies, immunisation. Making essential health care in obstetrics and neonatal for all and everywhere.
- 30 June 2021
- Published by Manipal College of Nursing, Manipal Academy of Higher Education in Manipal Journal of Medical Sciences
- Vol. 6 (1) , 6
Open AccessComparative study of Perinatal Mortality, Stillbirths, and Neonatal Mortality from 2010 to 2018 in developing and developed nations with reference to Malaysia
Background: Malaysia being an emerging economy has done well in the health sector. The perinatal mortality is reduced significantly but a slight upward trend was seen after 2015 in less developed states. This prompted us to conduct a review of perinatal, stillbirth, and neonatal deaths in Malaysia and compare them with other developing and developed countries. Aims and objectives: To find out: (1) Perinatal, neonatal and stillbirth rates from 2010 to 2018 in Malaysia, and (2) Compare it with developed and developing countries for the same duration. (3) To study contributary factors responsible for perinatal mortality, stillbirths and neonatal deaths and recommend the action plan to reduce it. Materials and Methods: Data related to perinatal, stillbirths and early neonatal mortality was searched from September 2020 to October 2020 using PubMed, Google, Google Scholar, Embase, EBSCO, Elsevier, and NIH/National Library of Medicine. Statistical Analysis: Analysis was done using Excel and StatCalc. Results: Mean perinatal mortality, stillbirth, and early neonatal mortality rates in Malaysia are 7.8, 4.72, 3 per 1000 respectively, which are almost half as that of Brazil which has PMR 17/1000, SBR 9.11/1000, ENMR 7.15/1000 live births. However, these values are twice as high as Singapore and Netherlands. Singapore has the lowest mortality rates; PMR 3.2, SBR 2.33 and ENMR 1.21 per 1000. Comparatively, India had the highest PMR of 26/1000 and ENMR of 22/1000 live births. Regional variations are seen in Malaysia, Brazil, India, and Netherlands. Main causes of perinatal mortality include pre-term births, hypertensive disorders of pregnancy, asphyxia, prematurity and low birth weight, congenital malformations in developing and emerging countries. Whereas, in developed nations, congenital malformation, aneuploidy, asphyxia and antepartum haemorrhage (APH) constitute the main causes. Major risk factors were maternal age, primigravida, obesity and diabetes. Conclusion: PMR, ENMR, SBR are high in low-income states in Malaysia, India, and Brazil. Contributory factors can be low income, poor education, lack of health-seeking behaviour. Mortalities can be reduced by educating women regarding pregnancy, nutrition, spacing of pregnancies, immunisation. Making essential health care in obstetrics and neonatal for all and everywhere.
- 3 March 2020
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (3) , CD012762
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease
Background Sickle cell disease (SCD), one of the most common inherited disorders, is associated with vaso‐occlusive pain episodes and haemolysis leading to recurrent morbidity, hospital admissions and work or school absenteeism. The crises are conventionally treated with opioids, non‐opioids and other adjuvants with the risk of developing complications, addictions and drug‐seeking behaviour. Different non‐pharmacological treatments, such as transcutaneous electrical nerve stimulation (TENS) have been used for managing pain in other painful conditions. Hence, the efficacy of TENS for managing pain in SCD needs to be reviewed. Objectives To assess the benefits and harms of TENS for managing pain in people with SCD who experience pain crises or chronic pain (or both). Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Register, comprising of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also searched online trial registries and the reference lists of relevant articles and reviews. Date of the last search: 26 Febraury 2020. Selection criteria We included randomised controlled trials (RCTs) and quasi‐RCTs, where TENS was evaluated for managing pain in people with SCD. Data collection and analysis Two review authors independently assessed the eligibility of the trials identified by the literature searches according to the inclusion criteria. Two review authors then independently extracted data, assessed for risk of bias using the Cochrane standard tool and rated the quality of evidence using the GRADE guidelines. Main results One double‐blind cross‐over RCT with 22 participants with SCD (aged 12 to 27 years) was eligible for inclusion. Following stratification into four pain crises severity grades, participants were then randomised to receive TENS or placebo (sham TENS). The trial was concluded after 60 treatment episodes (30 treatment episodes of each treatment group). There is a lack of clarity regarding the trial design and the analysis of the cross‐over data. If a participant was allocated to TENS treatment for an episode of pain and subsequently returned with a further episode of a similar degree of pain, they would then receive the sham TENS treatment (cross‐over design). For those experiencing a pain episode of a different severity, it is not clear whether they were re‐randomised or given the alternate treatment. Reporting and analysis was based on the total number pain events and not on the number of participants. It is unclear how many participants were crossed over from the TENS group to the sham TENS group and vice versa. The trial had a high risk of bias regarding random sequence generation and allocation concealment; an unclear risk regarding the blinding of participants and personnel; and a low risk regarding the blinding of the outcome assessors and selective outcome reporting. The trial was small and of very low quality; furthermore, given the issue with trial design we were unable to quantitatively analyse the data. Therefore, we present only a narrative summary and caution is advised in interpreting the results. In relation to our pre‐defined primary outcomes, the included trial did not report pain relief at two to four weeks post intervention. The trial authors reported that no difference was found in the changes in pain ratings (recorded at one hour and four hours post intervention) between the TENS and the placebo groups. In relation to our secondary outcomes, the analgesic usage during the trial also did not show any difference between groups. Given the quality of the evidence, we are uncertain whether TENS improves overall satisfaction as compared to sham TENS. The ability to cope with activities of daily living was not evaluated. Regarding adverse events, although one case of itching was reported in the TENS group, the site and nature of itching was not clearly stated; hence it cannot be clearly attributed to TENS. Also, two participants receiving 'sham' TENS reported a worsening of pain with the intervention. Authors' conclusions Since we have only included one small and very low‐quality trial, with a high risk of bias across several domains, we are unable to conclude whether TENS is harmful or beneficial for managing pain in people with SCD. There is a need for a well‐designed, adequately‐powered, RCT to evaluate the role of TENS in managing pain in people with SCD.
- 3 March 2020
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (3) , CD012762
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease
Background Sickle cell disease (SCD), one of the most common inherited disorders, is associated with vaso‐occlusive pain episodes and haemolysis leading to recurrent morbidity, hospital admissions and work or school absenteeism. The crises are conventionally treated with opioids, non‐opioids and other adjuvants with the risk of developing complications, addictions and drug‐seeking behaviour. Different non‐pharmacological treatments, such as transcutaneous electrical nerve stimulation (TENS) have been used for managing pain in other painful conditions. Hence, the efficacy of TENS for managing pain in SCD needs to be reviewed. Objectives To assess the benefits and harms of TENS for managing pain in people with SCD who experience pain crises or chronic pain (or both). Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Register, comprising of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also searched online trial registries and the reference lists of relevant articles and reviews. Date of the last search: 26 Febraury 2020. Selection criteria We included randomised controlled trials (RCTs) and quasi‐RCTs, where TENS was evaluated for managing pain in people with SCD. Data collection and analysis Two review authors independently assessed the eligibility of the trials identified by the literature searches according to the inclusion criteria. Two review authors then independently extracted data, assessed for risk of bias using the Cochrane standard tool and rated the quality of evidence using the GRADE guidelines. Main results One double‐blind cross‐over RCT with 22 participants with SCD (aged 12 to 27 years) was eligible for inclusion. Following stratification into four pain crises severity grades, participants were then randomised to receive TENS or placebo (sham TENS). The trial was concluded after 60 treatment episodes (30 treatment episodes of each treatment group). There is a lack of clarity regarding the trial design and the analysis of the cross‐over data. If a participant was allocated to TENS treatment for an episode of pain and subsequently returned with a further episode of a similar degree of pain, they would then receive the sham TENS treatment (cross‐over design). For those experiencing a pain episode of a different severity, it is not clear whether they were re‐randomised or given the alternate treatment. Reporting and analysis was based on the total number pain events and not on the number of participants. It is unclear how many participants were crossed over from the TENS group to the sham TENS group and vice versa. The trial had a high risk of bias regarding random sequence generation and allocation concealment; an unclear risk regarding the blinding of participants and personnel; and a low risk regarding the blinding of the outcome assessors and selective outcome reporting. The trial was small and of very low quality; furthermore, given the issue with trial design we were unable to quantitatively analyse the data. Therefore, we present only a narrative summary and caution is advised in interpreting the results. In relation to our pre‐defined primary outcomes, the included trial did not report pain relief at two to four weeks post intervention. The trial authors reported that no difference was found in the changes in pain ratings (recorded at one hour and four hours post intervention) between the TENS and the placebo groups. In relation to our secondary outcomes, the analgesic usage during the trial also did not show any difference between groups. Given the quality of the evidence, we are uncertain whether TENS improves overall satisfaction as compared to sham TENS. The ability to cope with activities of daily living was not evaluated. Regarding adverse events, although one case of itching was reported in the TENS group, the site and nature of itching was not clearly stated; hence it cannot be clearly attributed to TENS. Also, two participants receiving 'sham' TENS reported a worsening of pain with the intervention. Authors' conclusions Since we have only included one small and very low‐quality trial, with a high risk of bias across several domains, we are unable to conclude whether TENS is harmful or beneficial for managing pain in people with SCD. There is a need for a well‐designed, adequately‐powered, RCT to evaluate the role of TENS in managing pain in people with SCD.
- Open Access
- 1 January 2019
- Published by Medknow in Oman Journal of Ophthalmology
- Vol. 12 (3) , 160-165
Intraoperative and postoperative complications of cataract surgery in eyes with pseudoexfoliation – An 8-year analysis
INTRODUCTION: Pseudoexfoliation (PXM) is a fibrillar material deposited in the anterior chamber of the eye and can cause disintegration of zonules and make pupillary dilatation difficult. This can make surgery difficult and result in intraoperative and postoperative complications. The aim of this study was to learn about whether the presence of pseudoexfoliation caused significant complications during cataract surgery. MATERIALS AND METHODS: We did a secondary data analysis of 12,992 eyes from 2007 to 2014 using the National Eye Database of Melaka Hospital Malaysia on intraoperative and postoperative cataract surgery complications of patients with PXM. RESULTS: Patients with PXM were 2.68 times more likely to get intraoperative complications (P < 0.001). They had a higher incidence of lens subluxation, zonular dehiscence, and vitreous loss (P < 0.001). Although posterior capsule rupture (PCR) was the most common intraoperative complication during cataract surgery (4.8%), the presence of pseudoexfoliation was not associated with PCR (P > 0.05). We did not observe any association between patients with pseudoexfoliation and any of the postoperative complications such as corneal decompensation, raised intraocular pressure, and intraocular lens decentration (P > 0.05). Pseudoexfoliation did not cause corneal decompensation (P > 0.05) although corneal decompensation was the highest postoperative complication of cataract surgeries (0.18%). CONCLUSIONS: Patients with PXM had a higher rate of intraoperative complications which were mainly vitreous loss and zonular dehiscence and also lens subluxation/dislocation. We observed poorer visual outcomes in those with PXM following cataract surgery. Patients with pseudoexfoliation should be identified and precautions taken to minimize these complications to get better visual outcomes.
- 1 January 2019
- Published by Medknow in Oman Journal of Ophthalmology
- Vol. 12 (3) , 160-165
Open AccessIntraoperative and postoperative complications of cataract surgery in eyes with pseudoexfoliation – An 8-year analysis
INTRODUCTION: Pseudoexfoliation (PXM) is a fibrillar material deposited in the anterior chamber of the eye and can cause disintegration of zonules and make pupillary dilatation difficult. This can make surgery difficult and result in intraoperative and postoperative complications. The aim of this study was to learn about whether the presence of pseudoexfoliation caused significant complications during cataract surgery. MATERIALS AND METHODS: We did a secondary data analysis of 12,992 eyes from 2007 to 2014 using the National Eye Database of Melaka Hospital Malaysia on intraoperative and postoperative cataract surgery complications of patients with PXM. RESULTS: Patients with PXM were 2.68 times more likely to get intraoperative complications (P < 0.001). They had a higher incidence of lens subluxation, zonular dehiscence, and vitreous loss (P < 0.001). Although posterior capsule rupture (PCR) was the most common intraoperative complication during cataract surgery (4.8%), the presence of pseudoexfoliation was not associated with PCR (P > 0.05). We did not observe any association between patients with pseudoexfoliation and any of the postoperative complications such as corneal decompensation, raised intraocular pressure, and intraocular lens decentration (P > 0.05). Pseudoexfoliation did not cause corneal decompensation (P > 0.05) although corneal decompensation was the highest postoperative complication of cataract surgeries (0.18%). CONCLUSIONS: Patients with PXM had a higher rate of intraoperative complications which were mainly vitreous loss and zonular dehiscence and also lens subluxation/dislocation. We observed poorer visual outcomes in those with PXM following cataract surgery. Patients with pseudoexfoliation should be identified and precautions taken to minimize these complications to get better visual outcomes.
- Open Access
- 22 April 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 4 (4) , CD011633
Treatment of dental complications in sickle cell disease
Sickle cell disease is the most common single gene disorder and the commonest haemoglobinopathy found with high prevalence in many populations across the world. Management of dental complications in people with sickle cell disease requires special consideration for three main reasons. Firstly, dental and oral tissues are affected by the blood disorder resulting in several oro-facial abnormalities. Secondly, living with a haemoglobinopathy and coping with its associated serious consequences may result in individuals neglecting their oral health care. Finally, the treatment of these oral complications must be adapted to the systemic condition and special needs of these individuals, in order not to exacerbate or deteriorate their general health. Guidelines for the treatment of dental complications in this population who require special care are unclear and even unavailable in many aspects. Hence this review was undertaken to provide a basis for clinical care by investigating and analysing the existing evidence in the literature for the treatment of dental complications in people with sickle cell disease. To assess methods of treating dental complications in people with sickle cell disease. We searched the Cochrane Haemoglobinopathies Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. Date of last search: 11 April 2016. Additionally, we searched nine online databases (PubMed, Google Scholar, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Literature in the Health Sciences in Latin America and the Caribbean database, African Index Medicus, Index Medicus for South East Asia Region, Index Medicus for the Eastern Mediterranean Region, Indexing of Indian Medical Journals). We also searched the reference lists of relevant articles and reviews and contacted haematologists, experts in fields of dentistry, organizations, pharmaceutical companies and researchers working in this field. Date of last search: 03 March 2016. We searched for published or unpublished randomised controlled studies of treatments for dental complications in people with sickle cell disease. Two review authors intended to independently extract data and assess the risk of bias of the included studies using standard Cochrane methodologies; however, no studies were identified for inclusion in the review. No randomised controlled studies were identified. This Cochrane review did not identify any randomised controlled studies assessing interventions for the treatment of dental complications in people with sickle cell disease. There is an important need for randomised controlled studies in this area, so as to identify the most effective and safe method for treating dental complications in people with sickle cell disease.
- 22 April 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 4 (4) , CD011633
Open AccessTreatment of dental complications in sickle cell disease
Sickle cell disease is the most common single gene disorder and the commonest haemoglobinopathy found with high prevalence in many populations across the world. Management of dental complications in people with sickle cell disease requires special consideration for three main reasons. Firstly, dental and oral tissues are affected by the blood disorder resulting in several oro-facial abnormalities. Secondly, living with a haemoglobinopathy and coping with its associated serious consequences may result in individuals neglecting their oral health care. Finally, the treatment of these oral complications must be adapted to the systemic condition and special needs of these individuals, in order not to exacerbate or deteriorate their general health. Guidelines for the treatment of dental complications in this population who require special care are unclear and even unavailable in many aspects. Hence this review was undertaken to provide a basis for clinical care by investigating and analysing the existing evidence in the literature for the treatment of dental complications in people with sickle cell disease. To assess methods of treating dental complications in people with sickle cell disease. We searched the Cochrane Haemoglobinopathies Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. Date of last search: 11 April 2016. Additionally, we searched nine online databases (PubMed, Google Scholar, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Literature in the Health Sciences in Latin America and the Caribbean database, African Index Medicus, Index Medicus for South East Asia Region, Index Medicus for the Eastern Mediterranean Region, Indexing of Indian Medical Journals). We also searched the reference lists of relevant articles and reviews and contacted haematologists, experts in fields of dentistry, organizations, pharmaceutical companies and researchers working in this field. Date of last search: 03 March 2016. We searched for published or unpublished randomised controlled studies of treatments for dental complications in people with sickle cell disease. Two review authors intended to independently extract data and assess the risk of bias of the included studies using standard Cochrane methodologies; however, no studies were identified for inclusion in the review. No randomised controlled studies were identified. This Cochrane review did not identify any randomised controlled studies assessing interventions for the treatment of dental complications in people with sickle cell disease. There is an important need for randomised controlled studies in this area, so as to identify the most effective and safe method for treating dental complications in people with sickle cell disease.
- Open Access
- 16 February 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2015 (2) , CD010009
Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema
Diabetic cystoid macular oedema (CMO) is a condition which involves fluid accumulation in the inner portion of the retina. It often follows changes in retinal blood vessels which enhance the fluid to come out of vessels. Although it may be asymptomatic, symptoms are primarily painless loss of central vision, often with the complaint of seeing black spots in front of the eye.It is reported that CMO may resolve spontaneously, or fluctuate for months, before causing loss of vision. If left untreated or undiagnosed, progression of CMO may lead to permanent visual loss.It has been noted that patients with diabetic retinopathy have elevated inflammatory markers, and therefore it is likely that inflammation aids in the progression of vascular disease in these patients. Several topical non-steroidal anti-inflammatory drugs (NSAIDs) such as ketorolac 0.5%, bromfenac 0.09%, and nepafenac 0.1%, have therefore also been used topically to treat chronic diabetic CMO. Hence this review was conducted to find out the effects of topical NSAIDs in diabetic CMO. To assess the effects of topical non-steroidal anti-inflammatory drugs (NSAIDs) for diabetic cystoid macular oedema (CMO). We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 12), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to January 2015), EMBASE (January 1980 to January 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to January 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 12 January 2015. Randomised controlled trials (RCTs) and quasi-RCTs investigating the effects of topically applied NSAIDs in the treatment of people with diabetic CMO aged 18 years of age or over. Two review authors independently assessed trial eligibility and screened all available titles and abstracts for inclusion. There were no discrepancies and we did not have to contact trial investigators for missing data. We did not identify any RCTs matching the inclusion criteria for this review. The review did not identify any RCTs investigating the effects of topical NSAIDs in the treatment of diabetic CMO. Most of the studies identified through the electronic searches had been conducted to analyse the effect of topical NSAIDs for pseudophakic CMO.In the absence of high quality evidence, clinicians need to use their clinical judgement and other low level evidence, such as observational non-randomised trials, to decide whether to use topical NSAIDs in cases of diabetic CMO.More research is needed to better understand the cause of this condition and its pathophysiology. This systematic review has identified the need for well designed, adequately powered RCTs to assess possible beneficial and adverse effects of topical NSAIDs in people with diabetic CMO. Future trials should aim to include a large sample size with an adequate follow-up period of up to one year.
- 16 February 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2015 (2) , CD010009
Open AccessTopical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema
Diabetic cystoid macular oedema (CMO) is a condition which involves fluid accumulation in the inner portion of the retina. It often follows changes in retinal blood vessels which enhance the fluid to come out of vessels. Although it may be asymptomatic, symptoms are primarily painless loss of central vision, often with the complaint of seeing black spots in front of the eye.It is reported that CMO may resolve spontaneously, or fluctuate for months, before causing loss of vision. If left untreated or undiagnosed, progression of CMO may lead to permanent visual loss.It has been noted that patients with diabetic retinopathy have elevated inflammatory markers, and therefore it is likely that inflammation aids in the progression of vascular disease in these patients. Several topical non-steroidal anti-inflammatory drugs (NSAIDs) such as ketorolac 0.5%, bromfenac 0.09%, and nepafenac 0.1%, have therefore also been used topically to treat chronic diabetic CMO. Hence this review was conducted to find out the effects of topical NSAIDs in diabetic CMO. To assess the effects of topical non-steroidal anti-inflammatory drugs (NSAIDs) for diabetic cystoid macular oedema (CMO). We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 12), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to January 2015), EMBASE (January 1980 to January 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to January 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 12 January 2015. Randomised controlled trials (RCTs) and quasi-RCTs investigating the effects of topically applied NSAIDs in the treatment of people with diabetic CMO aged 18 years of age or over. Two review authors independently assessed trial eligibility and screened all available titles and abstracts for inclusion. There were no discrepancies and we did not have to contact trial investigators for missing data. We did not identify any RCTs matching the inclusion criteria for this review. The review did not identify any RCTs investigating the effects of topical NSAIDs in the treatment of diabetic CMO. Most of the studies identified through the electronic searches had been conducted to analyse the effect of topical NSAIDs for pseudophakic CMO.In the absence of high quality evidence, clinicians need to use their clinical judgement and other low level evidence, such as observational non-randomised trials, to decide whether to use topical NSAIDs in cases of diabetic CMO.More research is needed to better understand the cause of this condition and its pathophysiology. This systematic review has identified the need for well designed, adequately powered RCTs to assess possible beneficial and adverse effects of topical NSAIDs in people with diabetic CMO. Future trials should aim to include a large sample size with an adequate follow-up period of up to one year.